MDT · Insider Trading

Medtronic plc

Every open-market purchase and sale reported by MDT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
5
code S
Reporting Insiders
25
current holders
MDT — Recent Form 4 Transactions (latest 2026-11-04)
FiledInsiderRole TypeSharesValue
2026-11-04 Michael Marinaro President A +6,547 —
2026-10-21 Kevin E Lofton Director J −182 —
2026-10-16 Geoffrey Martha Chairman and CEO Sell −50,000 −$4.75M
2026-10-16 Michael Marinaro EVP, Pres MedSurg and Americas Sell −10,420 −$1.00M
2026-09-17 Harry Skip Kiil EVP & President Cardiovascular Sell −1,483 −$138.88K
2026-09-16 Denise L. Blomquist Chief Accounting Officer G −600 —
2026-08-24 Michael Marinaro EVP, Pres MedSurg and Americas F −1,084 −$100.05K
2026-08-04 Thierry Pieton EVP & Chief Financial Officer A +11,537 —
2026-08-04 Denise L. Blomquist Chief Accounting Officer MIXED +2,125 −$18.10K
2026-08-04 Kweli Thompson EVP & President, Neuroscience MIXED +5,184 −$148.49K
2026-08-04 Geoffrey Martha Chairman and CEO MIXED +25,723 −$1.35M
2026-08-04 Harry Skip Kiil EVP & President Cardiovascular MIXED +6,156 −$262.49K
2026-08-04 Michelle Quinn EVP, GC and Secretary A +6,346 —
2026-08-04 Michael Marinaro EVP, Pres MedSurg and Americas MIXED +53,751 −$286.57K
2026-08-04 Matthew R. Walter SVP, Chief HR Officer MIXED +4,094 −$143.03K
2026-07-29 Michelle Quinn EVP, GC and Secretary F −2,069 −$179.75K
2026-07-09 Matthew R. Walter SVP, Chief HR Officer Sell −3,102 −$257.93K
2026-06-09 Harry Skip Kiil EVP & President Cardiovascular Sell −4,189 −$336.97K
2026-06-08 Harry Skip Kiil EVP & President Cardiovascular F −6,817 −$567.99K
2026-06-08 Michael Marinaro EVP, Pres MedSurg and Americas F −7,471 −$622.48K
2026-06-08 Denise L. Blomquist Chief Accounting Officer F −237 −$19.75K
2026-06-08 Matthew R. Walter SVP, Chief HR Officer F −2,840 −$236.63K
2026-06-08 Geoffrey Martha Chairman and CEO F −41,936 −$3.49M
2026-05-28 Denise L. Blomquist Chief Accounting Officer M +1,712 —
2026-05-28 Harry Skip Kiil EVP & President Cardiovascular M +15,195 —
2026-05-28 Michael Marinaro EVP, Pres MedSurg and Americas M +18,994 —
2026-05-28 Geoffrey Martha Chairman and CEO M +94,963 —
2026-05-28 Brett A. Wall EVP & Pres Neuroscience M +26,907 —
2026-05-28 Matthew R. Walter SVP, Chief HR Officer M +9,149 —
2026-05-04 Matthew R. Walter SVP, Chief HR Officer F −35 −$2.80K
2026-04-29 Craig Arnold Director MIXED +1,904 −$16.95K
2026-04-29 Scott C Donnelly Director MIXED +1,904 −$16.95K
2026-04-29 Lidia Fonseca Director MIXED +1,904 −$16.95K
2026-04-29 John P Groetelaars Director A +1,444 —
2026-04-29 Randall J Hogan Director MIXED +1,904 −$16.95K
2026-04-29 William R Jellison Director A +1,444 —
2026-04-29 Joon Sup Lee Director A +1,803 —
2026-04-29 Gregory P Lewis Director MIXED +1,904 −$16.95K
2026-04-29 Kevin E Lofton Director MIXED +1,904 −$16.95K
2026-04-29 Elizabeth G Nabel Director MIXED +1,904 −$16.95K
2026-04-29 Kendall J Powell Director MIXED +1,904 −$16.95K
2026-04-29 Denise L. Blomquist Chief Accounting Officer MIXED +1,190 −$26.04K
2026-03-05 Thierry Pieton EVP & Chief Financial Officer F −2,976 −$287.81K
2026-02-26 Harry Skip Kiil EVP & President Cardiovascular MIXED −1,648 −$507.71K
2026-02-24 Denise L. Blomquist Chief Accounting Officer G −340 —
2026-02-02 Denise L. Blomquist Chief Accounting Officer F −148 −$14.95K
2025-12-17 Geoffrey Martha Chairman and CEO F −1,564 −$156.20K
2025-12-17 Michael Marinaro EVP, Pres MedSurg and Americas F −1,371 −$136.92K
2025-12-17 Brett A. Wall EVP & Pres Neuroscience F −439 −$43.84K
2025-12-09 Harry Skip Kiil EVP & President Cardiovascular F −1,702 −$172.51K
MDT — Current Insider Holders
InsiderRole Shares HeldValue
Geoffrey Martha Chairman and CEO 277,866 $27.86M
Michael Marinaro President 113,353 $11.37M
Randall J Hogan Director 86,082 $8.63M
Brett A. Wall EVP & Pres Neuroscience 82,183 $8.24M
Sean Salmon EVP & President Cardiovascular 64,722 $6.49M
Ivan K Fong EVP GENERAL COUNSEL & SECR 54,692 $5.48M
Kendall J Powell Director 54,380 $5.45M
Thierry Pieton EVP & Chief Financial Officer 49,645 $4.98M
Gregory L Smith EVP Global Ops & Supply Chain 46,016 $4.61M
Gary Louis Corona Interim CFO 44,255 $4.44M
Harry Skip Kiil EVP & President Cardiovascular 42,186 $4.23M
Craig Arnold Director 42,185 $4.23M
Matthew R. Walter SVP, Chief HR Officer 39,928 $4.00M
Kweli Thompson EVP & President, Neuroscience 35,390 $3.55M
Jennifer M Kirk Chief Accounting Officer 28,011 $2.81M
Michelle Quinn EVP, GC and Secretary 26,721 $2.68M
Scott C Donnelly Director 23,924 $2.40M
Elizabeth G Nabel Director 19,584 $1.96M
Denise L. Blomquist Chief Accounting Officer 16,398 $1.64M
Andrea Jo Goldsmith Director 10,247 $1.03M
Kevin E Lofton Director 9,977 $1.00M
Lidia Fonseca Director 7,644 $766.54K
William R Jellison Director 6,444 $646.20K
Gregory P Lewis Director 5,754 $577.01K
Joon Sup Lee Director 1,803 $180.80K
MDT Insider Trading FAQ
Who are the insiders at MDT?
25 officers, directors and 10%+ beneficial owners currently report holdings in MDT via SEC Form 4.
Are MDT insiders buying or selling?
Across the 50 most recent Form 4 filings for MDT, 0 were open-market purchases (code P) and 5 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is MDT insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent MDT filing is dated 2026-11-04.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the MDT quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.